Sep 30, 2026 · 7 min · 6 segments
Kodiak Sciences meets its primary endpoint in a phase 3 trial for its DME drug candidate clearing the way for a regulatory submission; the European Commission approves Roche’s Susvimo for wet AMD; and…
Briana ClarkHost
In our top story, Kodiak Sciences received a big win this week with its wet AMD drug candidate, Tarkosamab, which met its primary endpoints in a Phase 3 trial.
With the new data in hand, Kodiak plans to submit a regulatory submission in the fourth quarter of this year.
Kodiak announced positive top-line results from the Phase 3 Daybreak Study, reporting that both Tarkosamab, which is being branded as Zancuda, and Tabirfus-TED met the trial's primary endpoints in patients with wet AMD.
Kodiak said both investigational therapies achieved non-inferiority to a flip recept for vision gains at one year.
The company reported that Zancuda provided rapid clinical effects during the loading phase and enabled more than half of treated patients to reach a six-month treatment interval.
54% of Zancuda-treated patients achieved a 24-week treatment interval at year one under strict treat-to-dryness-retreatment criteria.
During a conference call with investors, Dr. Charles Wyckoff, chairman of research at the Retina Consultants of Texas, summarized the main findings of the Phase III trial of Tarkosimab.
In our top story, Kodiak Sciences received a big win this week with its wet AMD drug candidate, Tarkosamab, which met its primary endpoints in a Phase 3 trial.
With the new data in hand, Kodiak plans to submit a regulatory submission in the fourth quarter of this year.
Kodiak announced positive top-line results from the Phase 3 Daybreak Study, reporting that both Tarkosamab, which is being branded as Zancuda, and Tabirfus-TED met the trial's primary endpoints in patients with wet AMD.
Kodiak said both investigational therapies achieved non-inferiority to a flip recept for vision gains at one year.
The company reported that Zancuda provided rapid clinical effects during the loading phase and enabled more than half of treated patients to reach a six-month treatment interval.
54% of Zancuda-treated patients achieved a 24-week treatment interval at year one under strict treat-to-dryness-retreatment criteria.
During a conference call with investors, Dr. Charles Wyckoff, chairman of research at the Retina Consultants of Texas, summarized the main findings of the Phase III trial of Tarkosimab.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.
